Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction

Cinzia Nugara, Valentina Agnese, Giuseppina Novo, Giuseppa Caccamo, Laura Ajello

Risultato della ricerca: Article

Abstract

Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. Results. At baseline, 37% of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3-14.9 months) systolic blood pressure decreased from 117 +/- 14 to 101 +/- 12 mmHg (p < 0.0001), left ventricular ejection fraction (LVEF) increased from 27 +/- 6 to 29.7 +/- 7% (p < 0.0001), peak oxygen consumption (VO2) improved from 14.6 +/- 3.3 (% of predicted = 53.8 +/- 14.1) to 17.2 +/- 4.7 mL/kg/min (% of predicted = 64.7 +/- 17.8) (p < 0.0001), minute ventilation/carbon dioxide production relationship (VE/VCO2 Slope) decreased from 34.1 +/- 6.3 to 31.7 +/- 6.1 (p = 0.006), VO2 at anaerobic threshold increased from 11.3 +/- 2.6 to 12.6 +/- 3.5 mL/kg/min (p = 0.007), oxygen pulse increased from 11.5 +/- 3.0 to 13.4 +/- 4.3 mL/kg/min (p < 0.0001), and Delta VO2/Delta Work increased from 9.2 +/- 1.5 to 10.1 +/- 1.8 mL/min/watt (p = 0.0002). Conclusion. Sacubitril/valsartan improved exercise tolerance, LVEF, peak VO2, and ventilatory efficiency at 6.2 months follow-up. Further studies are necessary to better clarify underlying mechanisms of this functional improvement.
Lingua originaleEnglish
pagine (da-a)262-
Numero di pagine12
RivistaJournal of Clinical Medicine
Volume8
Stato di pubblicazionePublished - 2019

Fingerprint

Exercise Tolerance
Heart Failure
Stroke Volume
Blood Pressure
Anaerobic Threshold
Enalapril
Exercise Test
Carbon Dioxide
Oxygen Consumption
Observational Studies
Ventilation
Hospitalization
Oxygen
LCZ 696
Therapeutics

Cita questo

@article{d7e1ba6a70fd40dd9ed2f9f1e44fce6a,
title = "Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction",
abstract = "Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. Results. At baseline, 37{\%} of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3-14.9 months) systolic blood pressure decreased from 117 +/- 14 to 101 +/- 12 mmHg (p < 0.0001), left ventricular ejection fraction (LVEF) increased from 27 +/- 6 to 29.7 +/- 7{\%} (p < 0.0001), peak oxygen consumption (VO2) improved from 14.6 +/- 3.3 ({\%} of predicted = 53.8 +/- 14.1) to 17.2 +/- 4.7 mL/kg/min ({\%} of predicted = 64.7 +/- 17.8) (p < 0.0001), minute ventilation/carbon dioxide production relationship (VE/VCO2 Slope) decreased from 34.1 +/- 6.3 to 31.7 +/- 6.1 (p = 0.006), VO2 at anaerobic threshold increased from 11.3 +/- 2.6 to 12.6 +/- 3.5 mL/kg/min (p = 0.007), oxygen pulse increased from 11.5 +/- 3.0 to 13.4 +/- 4.3 mL/kg/min (p < 0.0001), and Delta VO2/Delta Work increased from 9.2 +/- 1.5 to 10.1 +/- 1.8 mL/min/watt (p = 0.0002). Conclusion. Sacubitril/valsartan improved exercise tolerance, LVEF, peak VO2, and ventilatory efficiency at 6.2 months follow-up. Further studies are necessary to better clarify underlying mechanisms of this functional improvement.",
keywords = "cardiopulmonary test, exercise tolerance, heart failure, sacubitril/valsartan",
author = "Cinzia Nugara and Valentina Agnese and Giuseppina Novo and Giuseppa Caccamo and Laura Ajello",
year = "2019",
language = "English",
volume = "8",
pages = "262--",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

}

TY - JOUR

T1 - Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction

AU - Nugara, Cinzia

AU - Agnese, Valentina

AU - Novo, Giuseppina

AU - Caccamo, Giuseppa

AU - Ajello, Laura

PY - 2019

Y1 - 2019

N2 - Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. Results. At baseline, 37% of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3-14.9 months) systolic blood pressure decreased from 117 +/- 14 to 101 +/- 12 mmHg (p < 0.0001), left ventricular ejection fraction (LVEF) increased from 27 +/- 6 to 29.7 +/- 7% (p < 0.0001), peak oxygen consumption (VO2) improved from 14.6 +/- 3.3 (% of predicted = 53.8 +/- 14.1) to 17.2 +/- 4.7 mL/kg/min (% of predicted = 64.7 +/- 17.8) (p < 0.0001), minute ventilation/carbon dioxide production relationship (VE/VCO2 Slope) decreased from 34.1 +/- 6.3 to 31.7 +/- 6.1 (p = 0.006), VO2 at anaerobic threshold increased from 11.3 +/- 2.6 to 12.6 +/- 3.5 mL/kg/min (p = 0.007), oxygen pulse increased from 11.5 +/- 3.0 to 13.4 +/- 4.3 mL/kg/min (p < 0.0001), and Delta VO2/Delta Work increased from 9.2 +/- 1.5 to 10.1 +/- 1.8 mL/min/watt (p = 0.0002). Conclusion. Sacubitril/valsartan improved exercise tolerance, LVEF, peak VO2, and ventilatory efficiency at 6.2 months follow-up. Further studies are necessary to better clarify underlying mechanisms of this functional improvement.

AB - Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. Results. At baseline, 37% of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3-14.9 months) systolic blood pressure decreased from 117 +/- 14 to 101 +/- 12 mmHg (p < 0.0001), left ventricular ejection fraction (LVEF) increased from 27 +/- 6 to 29.7 +/- 7% (p < 0.0001), peak oxygen consumption (VO2) improved from 14.6 +/- 3.3 (% of predicted = 53.8 +/- 14.1) to 17.2 +/- 4.7 mL/kg/min (% of predicted = 64.7 +/- 17.8) (p < 0.0001), minute ventilation/carbon dioxide production relationship (VE/VCO2 Slope) decreased from 34.1 +/- 6.3 to 31.7 +/- 6.1 (p = 0.006), VO2 at anaerobic threshold increased from 11.3 +/- 2.6 to 12.6 +/- 3.5 mL/kg/min (p = 0.007), oxygen pulse increased from 11.5 +/- 3.0 to 13.4 +/- 4.3 mL/kg/min (p < 0.0001), and Delta VO2/Delta Work increased from 9.2 +/- 1.5 to 10.1 +/- 1.8 mL/min/watt (p = 0.0002). Conclusion. Sacubitril/valsartan improved exercise tolerance, LVEF, peak VO2, and ventilatory efficiency at 6.2 months follow-up. Further studies are necessary to better clarify underlying mechanisms of this functional improvement.

KW - cardiopulmonary test

KW - exercise tolerance

KW - heart failure

KW - sacubitril/valsartan

UR - http://hdl.handle.net/10447/354548

M3 - Article

VL - 8

SP - 262-

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

ER -